HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
212:@0.078769:0.033217:0.109813:0.033217:0.109813:0.013052:0.078769:0.013052:0.010348:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
usually varies between three months and one year Cy-:@0.076190:0.084931:0.480927:0.084931:0.480927:0.069149:0.076190:0.069149:0.009192:0.005866:0.009192:0.010326:0.003024:0.003024:0.008104:0.004793:0.008376:0.010326:0.004551:0.003024:0.009827:0.005866:0.004778:0.010311:0.009827:0.005125:0.012564:0.009827:0.009827:0.009223:0.004762:0.005125:0.009223:0.004551:0.009827:0.009827:0.004762:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.004762:0.010326:0.009223:0.010357:0.004778:0.009903:0.009223:0.009827:0.004762:0.008104:0.009827:0.010326:0.004551:0.004778:0.012292:0.008104:0.005020
closporine A is usually considered the first-line agent for :@0.076190:0.099444:0.485160:0.099444:0.485160:0.083661:0.076190:0.083661:0.009782:0.003024:0.009903:0.005866:0.010311:0.009903:0.004551:0.003024:0.009223:0.009827:0.004596:0.011188:0.004596:0.003024:0.005866:0.004596:0.009192:0.005866:0.009192:0.010326:0.003024:0.003024:0.008104:0.004611:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.004596:0.005125:0.009223:0.009827:0.004596:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004596:0.010326:0.010175:0.009827:0.009223:0.005125:0.004581:0.004747:0.009903:0.004551:0.004188
those requiring systemic therapy.  Its long-term  use is :@0.076190:0.113957:0.485122:0.113959:0.485122:0.098176:0.076190:0.098174:0.005125:0.009223:0.009903:0.005866:0.009827:0.006940:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.003024:0.009223:0.010175:0.006940:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.006940:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.009713:0.006940:0.003417:0.005125:0.005866:0.006940:0.003024:0.009903:0.009223:0.010175:0.005020:0.005125:0.009827:0.004551:0.014182:0.004188:0.002737:0.009192:0.005866:0.009827:0.006940:0.003024:0.005866:0.700026
11:@0.324257:0.108660:0.333974:0.108660:0.333974:0.099506:0.324257:0.099506:0.004858:0.004858
limited by hypertension and renal toxicity.:@0.076197:0.128471:0.380710:0.128471:0.380710:0.112689:0.076197:0.112689:0.003024:0.003024:0.014182:0.003024:0.005125:0.009827:0.010357:0.004188:0.010311:0.008104:0.004188:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.010326:0.009223:0.010357:0.004188:0.004551:0.009827:0.009223:0.010326:0.003024:0.004188:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.004188
Azathioprine:@0.076197:0.158374:0.168424:0.158374:0.168424:0.141875:0.076197:0.141875:0.011188:0.006955:0.009979:0.004536:0.009071:0.003629:0.009676:0.009979:0.004838:0.003629:0.009071:0.009676
Azathioprine  (AZA) is a purine analogue that inhibits :@0.076197:0.175450:0.485152:0.175450:0.485152:0.159667:0.076197:0.159667:0.011188:0.006426:0.010326:0.005125:0.009223:0.003024:0.009903:0.010311:0.004551:0.003024:0.009223:0.009827:0.004188:0.003780:0.005579:0.011188:0.007257:0.011188:0.005579:0.007983:0.003024:0.005866:0.007983:0.010326:0.007983:0.010311:0.009192:0.004551:0.003024:0.009223:0.009827:0.007983:0.010326:0.009223:0.010326:0.003024:0.009903:0.010175:0.009192:0.009827:0.007983:0.005125:0.009223:0.010326:0.005125:0.007983:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.005866:0.004188
DNA production, and proliferation of B-cells and T-cells. :@0.076197:0.189962:0.485137:0.189962:0.485137:0.174180:0.076197:0.174180:0.011249:0.011188:0.011188:0.004445:0.010311:0.004551:0.009903:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004445:0.010326:0.009223:0.010357:0.004460:0.010311:0.004551:0.009903:0.003024:0.003024:0.004747:0.009827:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.004445:0.009903:0.004747:0.004460:0.008678:0.005020:0.009782:0.009827:0.003024:0.003024:0.005866:0.004460:0.010326:0.009223:0.010357:0.004460:0.006441:0.005020:0.009782:0.009827:0.003024:0.003024:0.005866:0.004188:0.004188
It is effective in treating refractory atopic dermatitis in :@0.076197:0.204475:0.485152:0.204475:0.485152:0.188692:0.076197:0.188692:0.003417:0.005125:0.006108:0.003024:0.005866:0.006108:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.006108:0.003024:0.009223:0.006108:0.005125:0.004551:0.009827:0.010326:0.005125:0.003024:0.009223:0.010175:0.006093:0.004551:0.009827:0.004747:0.004551:0.010326:0.009782:0.005125:0.009903:0.004551:0.008104:0.006093:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.006108:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.006108:0.003024:0.009223:0.004188
adults and children.  The  onset  of  action  is slow, with :@0.076197:0.218988:0.485137:0.218988:0.485137:0.203205:0.076197:0.203205:0.010326:0.010357:0.009192:0.003024:0.005125:0.005866:0.007333:0.010326:0.009223:0.010357:0.007333:0.009782:0.009223:0.003024:0.003024:0.010357:0.004551:0.009827:0.009223:0.004188:0.004188:0.003130:0.006441:0.009223:0.009827:0.004188:0.003130:0.009903:0.009223:0.005866:0.009827:0.005125:0.004188:0.003130:0.009903:0.004747:0.004188:0.003130:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.003130:0.003024:0.005866:0.007333:0.005866:0.003024:0.009903:0.012564:0.004188:0.007333:0.012564:0.003024:0.005125:0.009223:0.004188
maximal  efficacy  attained  at  8-12  weeks.  A  starting :@0.076197:0.233500:0.485122:0.233500:0.485122:0.217718:0.076197:0.217718:0.014182:0.010326:0.007257:0.003024:0.014182:0.010326:0.003024:0.004188:0.004264:0.009827:0.004747:0.003681:0.003681:0.009782:0.010326:0.009782:0.008104:0.004188:0.004248:0.010326:0.005125:0.005125:0.010326:0.003024:0.009223:0.009827:0.010357:0.004188:0.004248:0.010326:0.005125:0.004188:0.004248:0.008376:0.005020:0.008376:0.008376:0.004188:0.004264:0.012564:0.009827:0.009827:0.007590:0.005866:0.004188:0.004188:0.004248:0.011188:0.004188:0.004248:0.005866:0.005125:0.010326:0.004551:0.005125:0.003024:0.009223:0.010175:0.004188
dose of 50 mg/day is recommended. The dose may be :@0.076197:0.248013:0.485137:0.248013:0.485137:0.232230:0.076197:0.232230:0.010357:0.009903:0.005866:0.009827:0.004264:0.009903:0.004747:0.004264:0.008376:0.008376:0.004264:0.014182:0.010175:0.006607:0.010357:0.010326:0.008104:0.004264:0.003024:0.005866:0.004264:0.004551:0.009827:0.009782:0.009903:0.014182:0.014167:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.004264:0.006441:0.009223:0.009827:0.004264:0.010357:0.009903:0.005866:0.009827:0.004264:0.014182:0.010326:0.008104:0.004264:0.010311:0.009827:0.004188
increased to the maintenance dose of 2-3 mg/kg/day. :@0.076197:0.262525:0.485122:0.262525:0.485122:0.246743:0.076197:0.246743:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.004566:0.005125:0.009903:0.004566:0.005125:0.009223:0.009827:0.004566:0.014182:0.010326:0.003024:0.009223:0.005125:0.009827:0.009223:0.010326:0.009223:0.009782:0.009827:0.004566:0.010357:0.009903:0.005866:0.009827:0.004566:0.009903:0.004747:0.004566:0.008376:0.005020:0.008376:0.004581:0.014182:0.010175:0.006607:0.007590:0.010175:0.006607:0.010357:0.010326:0.008104:0.004188:0.004188
Low thiopurine-methyl transferase (TpMT) activity is asso-:@0.076197:0.277038:0.480964:0.277038:0.480964:0.261255:0.076197:0.261255:0.006985:0.009903:0.012564:0.003583:0.005125:0.009223:0.003024:0.009903:0.010311:0.009192:0.004551:0.003024:0.009223:0.009827:0.005020:0.014182:0.009827:0.005125:0.009223:0.008104:0.003024:0.003583:0.005125:0.004551:0.010326:0.009223:0.005866:0.004747:0.009827:0.004536:0.010326:0.005866:0.009827:0.003598:0.005579:0.006441:0.008950:0.013894:0.006441:0.005579:0.003583:0.010326:0.009782:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.003598:0.003024:0.005866:0.003598:0.010326:0.005866:0.005866:0.009903:0.005020
ciated with increased risk of myelotoxicity. Baseline TpMT :@0.076197:0.291551:0.485137:0.291551:0.485137:0.275768:0.076197:0.275768:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.003115:0.012564:0.003024:0.005125:0.009223:0.003115:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.003115:0.004551:0.003024:0.005866:0.007590:0.003115:0.009903:0.004747:0.003115:0.014182:0.008104:0.009827:0.003024:0.009903:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.004188:0.003115:0.008678:0.010326:0.005866:0.009827:0.003024:0.003024:0.009223:0.009827:0.003130:0.006441:0.008950:0.013894:0.006441:0.004188
screening can identify those at risk. Adverse effects in-:@0.076197:0.306063:0.480949:0.306063:0.480949:0.290281:0.076197:0.290281:0.005866:0.009782:0.004551:0.009827:0.009827:0.009223:0.003024:0.009223:0.010175:0.005337:0.009782:0.010326:0.009223:0.005337:0.003024:0.010357:0.009827:0.009223:0.005125:0.003024:0.004747:0.008104:0.005337:0.005125:0.009223:0.009903:0.005866:0.009827:0.005337:0.010326:0.005125:0.005337:0.004551:0.003024:0.005866:0.007590:0.004188:0.005337:0.011188:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.005337:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.005337:0.003024:0.009223:0.005020
clude gastro-intestinal (GIT) disturbances, elevated liver :@0.076197:0.320576:0.485137:0.320576:0.485137:0.304793:0.076197:0.304793:0.009782:0.003024:0.009192:0.010357:0.009827:0.004097:0.010175:0.010326:0.005866:0.005125:0.004551:0.009903:0.005020:0.003024:0.009223:0.005125:0.009827:0.005866:0.005125:0.003024:0.009223:0.010326:0.003024:0.004097:0.005579:0.013184:0.003417:0.006441:0.005579:0.004097:0.010357:0.003024:0.005866:0.005125:0.009192:0.004551:0.010311:0.010326:0.009223:0.009782:0.009827:0.005866:0.004188:0.004097:0.009827:0.003024:0.009827:0.008376:0.010326:0.005125:0.009827:0.010357:0.004097:0.003024:0.003024:0.008376:0.009827:0.004551:0.004188
enzymes, hypersensitivity  reactions and myelo toxicity. :@0.076197:0.335089:0.485152:0.335089:0.485152:0.319306:0.076197:0.319306:0.009827:0.009223:0.006426:0.008104:0.014182:0.009827:0.005866:0.004188:0.007605:0.009223:0.008104:0.010311:0.009827:0.004551:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.004188:0.003432:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.007605:0.010326:0.009223:0.010357:0.007605:0.014182:0.008104:0.009827:0.003024:0.009903:0.000000:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.004188:0.004188
It has been associated with an increased risk of non-:@0.076197:0.349601:0.480934:0.349601:0.480934:0.333819:0.076197:0.333819:0.003417:0.005125:0.006652:0.009223:0.010326:0.005866:0.006652:0.010311:0.009827:0.009827:0.009223:0.006652:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.006652:0.012564:0.003024:0.005125:0.009223:0.006652:0.010326:0.009223:0.006652:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.006652:0.004551:0.003024:0.005866:0.007590:0.006652:0.009903:0.004747:0.006652:0.009223:0.009903:0.009223:0.005020
melanoma skin cancer and lymphoma.:@0.076197:0.364114:0.366483:0.364114:0.366483:0.348331:0.076197:0.348331:0.014182:0.009827:0.003024:0.010326:0.009223:0.009903:0.014182:0.010326:0.004188:0.005866:0.007590:0.003024:0.009223:0.004188:0.009782:0.010326:0.009223:0.009782:0.009827:0.004551:0.004188:0.010326:0.009223:0.010357:0.004188:0.003024:0.008104:0.014182:0.010311:0.009223:0.009903:0.014182:0.010326:0.004188
11:@0.366464:0.358838:0.376180:0.358838:0.376180:0.349684:0.366464:0.349684:0.004858:0.004858
methotrexate:@0.076190:0.394044:0.174464:0.394044:0.174464:0.377545:0.076190:0.377545:0.013607:0.009676:0.004536:0.009071:0.009676:0.004536:0.004838:0.009676:0.008467:0.009979:0.004536:0.009676
Methotrexate  is  a folate antagonist and blocks DNA, :@0.076190:0.411120:0.485130:0.411120:0.485130:0.395337:0.076190:0.395337:0.013894:0.009827:0.005125:0.009223:0.009903:0.005125:0.004551:0.009827:0.007257:0.010326:0.005125:0.009827:0.004188:0.002948:0.003024:0.005866:0.004188:0.002978:0.010326:0.007151:0.004747:0.009903:0.003024:0.010326:0.005125:0.009827:0.007151:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.007151:0.010326:0.009223:0.010357:0.007151:0.010311:0.003024:0.009903:0.009782:0.007590:0.005866:0.007151:0.011249:0.011188:0.011188:0.004188:0.004188
RNA and purine synthesis. Methotrexate is equally effec-:@0.076190:0.425632:0.480957:0.425632:0.480957:0.409850:0.076190:0.409850:0.009177:0.011188:0.011188:0.003447:0.010326:0.009223:0.010357:0.003462:0.010311:0.009192:0.004551:0.003024:0.009223:0.009827:0.003462:0.005866:0.008104:0.009223:0.005125:0.009223:0.009827:0.005866:0.003024:0.005866:0.004188:0.003462:0.013894:0.009827:0.005125:0.009223:0.009903:0.005125:0.004551:0.009827:0.007257:0.010326:0.005125:0.009827:0.003447:0.003024:0.005866:0.003462:0.009827:0.010311:0.009192:0.010326:0.003024:0.003024:0.008104:0.003462:0.009827:0.004747:0.004747:0.009827:0.009782:0.005020
tive to AZA in atopic dermatitis in adults and children.  :@0.076190:0.440145:0.485140:0.440150:0.485140:0.424368:0.076190:0.424362:0.005125:0.003024:0.008376:0.009827:0.004747:0.005125:0.009903:0.004732:0.011188:0.007257:0.011188:0.004732:0.003024:0.009223:0.004747:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.004747:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004747:0.003024:0.009223:0.004747:0.010326:0.010357:0.009192:0.003024:0.005125:0.005866:0.004747:0.010326:0.009223:0.010357:0.004747:0.009782:0.009223:0.003024:0.003024:0.010357:0.004551:0.009827:0.009223:0.004188:0.009686:0.272852
13:@0.471233:0.434852:0.480949:0.434852:0.480949:0.425698:0.471233:0.425698:0.004858:0.004858
Its onset of action is slow and maximal clinical efficacy :@0.076185:0.454663:0.485155:0.454663:0.485155:0.438880:0.076185:0.438880:0.003417:0.005125:0.005866:0.004974:0.009903:0.009223:0.005866:0.009827:0.005125:0.004974:0.009903:0.004747:0.004974:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004974:0.003024:0.005866:0.004974:0.005866:0.003024:0.009903:0.012564:0.004974:0.010326:0.009223:0.010357:0.004974:0.014182:0.010326:0.007257:0.003024:0.014182:0.010326:0.003024:0.004974:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.004989:0.009827:0.004747:0.003681:0.003681:0.009782:0.010326:0.009782:0.008104:0.004188
is reached  at 8-12 weeks. The recommended  dose is :@0.076185:0.469176:0.485125:0.469176:0.485125:0.453393:0.076185:0.453393:0.003024:0.005866:0.006773:0.004551:0.009827:0.010326:0.009782:0.009223:0.009827:0.010357:0.004188:0.002570:0.010326:0.005125:0.006773:0.008376:0.005020:0.008376:0.008376:0.006773:0.012564:0.009827:0.009827:0.007590:0.005866:0.004188:0.006773:0.006441:0.009223:0.009827:0.006773:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.002570:0.010357:0.009903:0.005866:0.009827:0.006773:0.003024:0.005866:0.004188
7,5 mg-25 mg/week for adults and 10-20 mg/m /week :@0.076185:0.483688:0.485143:0.483691:0.485143:0.467909:0.076185:0.467906:0.008376:0.004188:0.008376:0.005564:0.014182:0.010175:0.005020:0.008376:0.008376:0.005579:0.014182:0.010175:0.006607:0.012564:0.009827:0.009827:0.007590:0.005564:0.004747:0.009903:0.004551:0.005564:0.010326:0.010357:0.009192:0.003024:0.005125:0.005866:0.005564:0.010326:0.009223:0.010357:0.005564:0.008376:0.008376:0.005020:0.008376:0.008376:0.005594:0.014182:0.010175:0.006607:0.014182:0.004856:0.006607:0.012564:0.009827:0.009827:0.007590:0.215831
2:@0.429680:0.478393:0.434538:0.478393:0.434538:0.469239:0.429680:0.469239:0.004858
for  children. Methotrexate  causes treatment-limiting :@0.076188:0.498204:0.485143:0.498204:0.485143:0.482421:0.076188:0.482421:0.004747:0.009903:0.004551:0.004188:0.006395:0.009782:0.009223:0.003024:0.003024:0.010357:0.004551:0.009827:0.009223:0.004188:0.010598:0.013894:0.009827:0.005125:0.009223:0.009903:0.005125:0.004551:0.009827:0.007257:0.010326:0.005125:0.009827:0.004188:0.006395:0.009782:0.010326:0.009192:0.005866:0.009827:0.005866:0.010598:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005020:0.003024:0.003024:0.014182:0.003024:0.005125:0.003024:0.009223:0.010175:0.004188
nausea and vomiting, hepatotoxicity and myelotoxic-:@0.076188:0.512717:0.480940:0.512717:0.480940:0.496934:0.076188:0.496934:0.009223:0.010326:0.009192:0.005866:0.009827:0.010326:0.006350:0.010326:0.009223:0.010357:0.006350:0.008376:0.009903:0.014182:0.003024:0.005125:0.003024:0.009223:0.010175:0.004188:0.006350:0.009223:0.009827:0.010311:0.010326:0.005125:0.009903:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.006350:0.010326:0.009223:0.010357:0.006350:0.014182:0.008104:0.009827:0.003024:0.009903:0.005125:0.009903:0.007257:0.003024:0.009782:0.005020
ity. It is teratogenic and women of child-bearing age :@0.076188:0.527229:0.485112:0.527229:0.485112:0.511447:0.076188:0.511447:0.003024:0.005125:0.008104:0.004188:0.006441:0.003417:0.005125:0.006441:0.003024:0.005866:0.006456:0.005125:0.009827:0.004551:0.010326:0.005125:0.009903:0.010175:0.009827:0.009223:0.003024:0.009782:0.006426:0.010326:0.009223:0.010357:0.006441:0.012564:0.009903:0.014182:0.009827:0.009223:0.006441:0.009903:0.004747:0.006441:0.009782:0.009223:0.003024:0.003024:0.010357:0.005020:0.010311:0.009827:0.010326:0.004551:0.003024:0.009223:0.010175:0.006441:0.010326:0.010175:0.009827:0.004188
must be on effective contraception. Folate supplemen-:@0.076188:0.541742:0.480924:0.541742:0.480924:0.525959:0.076188:0.525959:0.014182:0.009192:0.005866:0.005125:0.003870:0.010311:0.009827:0.003870:0.009903:0.009223:0.003870:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.003870:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.009782:0.009812:0.010311:0.005125:0.003024:0.009903:0.009223:0.004188:0.003870:0.007333:0.009903:0.003024:0.010326:0.005125:0.009827:0.003870:0.005866:0.009192:0.010311:0.010311:0.003024:0.009827:0.014182:0.009827:0.009223:0.005020
tation is essential to prevent myelosuppression.:@0.076188:0.556254:0.416291:0.556254:0.416291:0.540472:0.076188:0.540472:0.005125:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.003024:0.005866:0.004188:0.009827:0.005866:0.005866:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.004188:0.005125:0.009903:0.004188:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.004188:0.014182:0.008104:0.009827:0.003024:0.009903:0.005866:0.009192:0.010311:0.010311:0.004551:0.009827:0.005866:0.005866:0.003024:0.009903:0.009223:0.004188
mycophenolate mofetil:@0.076188:0.586157:0.247033:0.586157:0.247033:0.569659:0.076188:0.569659:0.013607:0.008769:0.009676:0.009676:0.009979:0.009071:0.009676:0.009071:0.009676:0.003629:0.009979:0.004536:0.009676:0.004233:0.014212:0.009676:0.004233:0.009676:0.004536:0.003629:0.003629
Mycophenolate mofetil (MMF) is an immunosuppressant :@0.076188:0.603233:0.485128:0.603233:0.485128:0.587450:0.076188:0.587450:0.013894:0.008104:0.009782:0.009903:0.010311:0.009223:0.009827:0.009223:0.009903:0.003024:0.010326:0.005125:0.009827:0.003099:0.014182:0.009903:0.004747:0.009827:0.005125:0.003024:0.003024:0.003115:0.005579:0.013894:0.013894:0.007333:0.005579:0.003115:0.003024:0.005866:0.003115:0.010326:0.009223:0.003115:0.003024:0.014182:0.014182:0.009192:0.009223:0.009903:0.005866:0.009192:0.010311:0.010311:0.004551:0.009827:0.005866:0.005866:0.010326:0.009223:0.005125:0.004188
that blocks the biosynthesis  of purines and selectively :@0.076188:0.617745:0.485128:0.617745:0.485128:0.601963:0.076188:0.601963:0.005125:0.009223:0.010326:0.005125:0.006652:0.010311:0.003024:0.009903:0.009782:0.007590:0.005866:0.006652:0.005125:0.009223:0.009827:0.006652:0.010311:0.003024:0.009903:0.005866:0.008104:0.009223:0.005125:0.009223:0.009827:0.005866:0.003024:0.005866:0.004188:0.002480:0.009903:0.004747:0.006652:0.010311:0.009192:0.004551:0.003024:0.009223:0.009827:0.005866:0.006652:0.010326:0.009223:0.010357:0.006652:0.005866:0.009827:0.003024:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.003024:0.008104:0.004188
affects B-cells and T-cells. It is an alternative systemic :@0.076188:0.632258:0.485158:0.632258:0.485158:0.616475:0.076188:0.616475:0.010326:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.006819:0.008678:0.005020:0.009782:0.009827:0.003024:0.003024:0.005866:0.006819:0.010326:0.009223:0.010357:0.006819:0.006441:0.005020:0.009782:0.009827:0.003024:0.003024:0.005866:0.004188:0.006819:0.003417:0.005125:0.006819:0.003024:0.005866:0.006819:0.010326:0.009223:0.006819:0.010326:0.003024:0.005125:0.009827:0.004551:0.009223:0.010326:0.005125:0.003024:0.008376:0.009827:0.006819:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.004188
agent  for  refractory  cases of  atopic dermatitis, with :@0.076188:0.646771:0.485143:0.646771:0.485143:0.630988:0.076188:0.630988:0.010326:0.010175:0.009827:0.009223:0.005125:0.004188:0.004248:0.004747:0.009903:0.004551:0.004188:0.004248:0.004551:0.009827:0.004747:0.004551:0.010326:0.009782:0.005125:0.009903:0.004551:0.008104:0.004188:0.004248:0.009782:0.010326:0.005866:0.009827:0.005866:0.008452:0.009903:0.004747:0.004188:0.004248:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.008452:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188:0.008452:0.012564:0.003024:0.005125:0.009223:0.004188
variable efficacy.:@0.076188:0.661283:0.205456:0.661283:0.205456:0.645501:0.076188:0.645501:0.008376:0.010326:0.004551:0.003024:0.010326:0.010311:0.003024:0.009827:0.005382:0.009827:0.004747:0.003681:0.003681:0.009782:0.010326:0.009782:0.008104:0.004188
11,14:@0.205460:0.656002:0.227321:0.656002:0.227321:0.646848:0.205460:0.646848:0.004858:0.004858:0.002429:0.004858:0.004858
 The onset of action is slower than :@0.227327:0.661301:0.485152:0.661301:0.485152:0.645518:0.227327:0.645518:0.005382:0.006441:0.009223:0.009827:0.005367:0.009903:0.009223:0.005866:0.009827:0.005125:0.005367:0.009903:0.004747:0.005382:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005382:0.003024:0.005866:0.005382:0.005866:0.003024:0.009903:0.012564:0.009827:0.004551:0.005382:0.005125:0.009223:0.010326:0.009223:0.004188
cyclosporine A and the recommended dose is 2 g/day. :@0.076197:0.675813:0.485137:0.675813:0.485137:0.660031:0.076197:0.660031:0.009782:0.008104:0.009782:0.003024:0.009903:0.005866:0.010311:0.009903:0.004551:0.003024:0.009223:0.009827:0.003901:0.011188:0.003901:0.010326:0.009223:0.010357:0.003901:0.005125:0.009223:0.009827:0.003901:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.003886:0.010357:0.009903:0.005866:0.009827:0.003901:0.003024:0.005866:0.003901:0.008376:0.003901:0.010175:0.006607:0.010357:0.010326:0.008104:0.004188:0.004188
side effects include gastro-intestinal disturbances, hae-:@0.076197:0.690326:0.480964:0.690326:0.480964:0.674543:0.076197:0.674543:0.007529:0.003024:0.010357:0.009827:0.004581:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004566:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.004581:0.010175:0.010326:0.005866:0.005125:0.004551:0.009903:0.005020:0.003024:0.009223:0.005125:0.009827:0.005866:0.005125:0.003024:0.009223:0.010326:0.003024:0.004581:0.010357:0.003024:0.005866:0.005125:0.009192:0.004551:0.010311:0.010326:0.009223:0.009782:0.009827:0.005866:0.004188:0.004581:0.009223:0.010326:0.009827:0.005020
matological abnormalities and teratogenicity.:@0.076197:0.704839:0.413503:0.704839:0.413503:0.689056:0.076197:0.689056:0.014182:0.010326:0.005125:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.010326:0.003024:0.004188:0.010326:0.010311:0.009223:0.009903:0.004551:0.014182:0.010326:0.003024:0.003024:0.005125:0.003024:0.009827:0.005866:0.004188:0.010326:0.009223:0.010357:0.004188:0.005125:0.009827:0.004551:0.010326:0.005125:0.009903:0.010175:0.009827:0.009223:0.003024:0.009782:0.003024:0.005125:0.008104:0.004188
systemic corticosteroids:@0.076197:0.734741:0.252787:0.734741:0.252787:0.718243:0.076197:0.718243:0.007862:0.008769:0.006652:0.004536:0.009676:0.014212:0.003629:0.009676:0.004233:0.009676:0.009676:0.004838:0.004536:0.003629:0.009676:0.009676:0.006652:0.004536:0.009676:0.004838:0.009676:0.003629:0.009979:0.006652
systemic corticosteroids are not recommended for the :@0.076197:0.751817:0.485167:0.751817:0.485167:0.736034:0.076197:0.736034:0.007529:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.005080:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.005866:0.005125:0.009827:0.004551:0.009903:0.003024:0.010357:0.005866:0.005065:0.010326:0.004551:0.009827:0.005065:0.009223:0.009903:0.005125:0.005065:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.005065:0.004747:0.009903:0.004551:0.005065:0.005125:0.009223:0.009827:0.004188
continuous or chronic intermittent treatment of atopic :@0.076197:0.766330:0.485137:0.766330:0.485137:0.750547:0.076197:0.750547:0.009782:0.009903:0.009223:0.005125:0.003024:0.009223:0.009192:0.009903:0.009192:0.005866:0.005760:0.009903:0.004551:0.005760:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.005760:0.003024:0.009223:0.005125:0.009827:0.004551:0.014182:0.003024:0.005125:0.005125:0.009827:0.009223:0.005125:0.005760:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005760:0.009903:0.004747:0.005760:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.004188
dermatitis.  Although  rapidly  effective, they have an :@0.076197:0.780842:0.485128:0.780856:0.485128:0.765073:0.076197:0.765060:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188:0.009713:0.007272:0.011188:0.003024:0.005125:0.009223:0.009903:0.009192:0.010175:0.009223:0.004188:0.003069:0.004551:0.010326:0.010311:0.003024:0.010357:0.003024:0.008104:0.004188:0.003099:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.004188:0.007272:0.005125:0.009223:0.009827:0.008104:0.007272:0.009223:0.010326:0.008376:0.009827:0.007272:0.010326:0.009223:-0.173298
14:@0.151786:0.775557:0.161502:0.775557:0.161502:0.766403:0.151786:0.766403:0.004858:0.004858
unfavourable risk/benefit profile and a high rate of re:@0.076188:0.795241:0.475936:0.795241:0.475936:0.779459:0.076188:0.779459:0.009192:0.009223:0.004747:0.010326:0.008376:0.009903:0.009192:0.004551:0.010326:0.010311:0.003024:0.009827:0.005715:0.004551:0.003024:0.005866:0.007590:0.006607:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005715:0.010311:0.004551:0.009903:0.003681:0.003681:0.003024:0.009827:0.005715:0.010326:0.009223:0.010357:0.005715:0.010326:0.005715:0.009223:0.003024:0.010175:0.009223:0.005715:0.004551:0.010326:0.005125:0.009827:0.005715:0.009903:0.004747:0.005715:0.004551:0.009827
-:@0.475936:0.795241:0.480955:0.795241:0.480955:0.779459:0.475936:0.779459:0.005020
lapse or rebound on withdrawal. In acute cases, they :@0.076188:0.809627:0.485128:0.809627:0.485128:0.793844:0.076188:0.793844:0.003024:0.010326:0.010311:0.005866:0.009827:0.006032:0.009903:0.004551:0.006017:0.004551:0.009827:0.010311:0.009903:0.009192:0.009223:0.010357:0.006017:0.009903:0.009223:0.006017:0.012564:0.003024:0.005125:0.009223:0.010357:0.004551:0.010326:0.012564:0.010326:0.003024:0.004188:0.006017:0.003417:0.009223:0.006017:0.010326:0.009782:0.009192:0.005125:0.009827:0.006017:0.009782:0.010326:0.005866:0.009827:0.005866:0.004188:0.006017:0.005125:0.009223:0.009827:0.008104:0.004188
may be used to gain rapid control, followed by rapid :@0.076188:0.824013:0.485143:0.824013:0.485143:0.808230:0.076188:0.808230:0.014182:0.010326:0.008104:0.006048:0.010311:0.009827:0.006048:0.009192:0.005866:0.009827:0.010357:0.006048:0.005125:0.009903:0.006032:0.010175:0.010326:0.003024:0.009223:0.006048:0.004551:0.010326:0.010311:0.003024:0.010357:0.006048:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.004188:0.006032:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.009827:0.010357:0.006048:0.010311:0.008104:0.006048:0.004551:0.010326:0.010311:0.003024:0.010357:0.004188
tapering and replacement with topical, phototherapy :@0.076188:0.838398:0.485128:0.838398:0.485128:0.822616:0.076188:0.822616:0.005125:0.010326:0.010311:0.009827:0.004551:0.003024:0.009223:0.010175:0.005745:0.010326:0.009223:0.010357:0.005745:0.004551:0.009827:0.010311:0.003024:0.010326:0.009782:0.009827:0.014182:0.009827:0.009223:0.005125:0.005745:0.012564:0.003024:0.005125:0.009223:0.005745:0.005125:0.009903:0.010311:0.003024:0.009782:0.010326:0.003024:0.004188:0.005745:0.010311:0.009223:0.009903:0.005125:0.009903:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188
or systemic treatment.:@0.076188:0.852784:0.238295:0.852784:0.238295:0.837001:0.076188:0.837001:0.009903:0.004551:0.004188:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.004188:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188
11,14:@0.238277:0.847484:0.260138:0.847484:0.260138:0.838330:0.238277:0.838330:0.004858:0.004858:0.002429:0.004858:0.004858
biologics:@0.076190:0.885650:0.148762:0.885650:0.148762:0.867318:0.076190:0.867318:0.009743:0.004032:0.010751:0.004032:0.010751:0.011087:0.004032:0.010751:0.007392
Dipulimab :@0.076190:0.902207:0.155112:0.902207:0.155112:0.885708:0.076190:0.885708:0.010583:0.003629:0.009979:0.009071:0.003629:0.003629:0.014212:0.009979:0.009979:0.004233
is a human monoclonal antibody against the :@0.154567:0.902207:0.485160:0.902207:0.485160:0.886424:0.154567:0.886424:0.003024:0.005866:0.003659:0.010326:0.003659:0.009223:0.009192:0.014182:0.010326:0.009223:0.003644:0.014182:0.009903:0.009223:0.009903:0.009782:0.003024:0.009903:0.009223:0.010326:0.003024:0.003659:0.010326:0.009223:0.005125:0.003024:0.010311:0.009903:0.010357:0.008104:0.003659:0.010326:0.010175:0.010326:0.003024:0.009223:0.005866:0.005125:0.003659:0.005125:0.009223:0.009827:0.004188
alpha subunit of the IL-4 receptor. It is the only biologic :@0.076190:0.916592:0.485130:0.916592:0.485130:0.900810:0.076190:0.900810:0.010326:0.003024:0.010311:0.009223:0.010326:0.004793:0.005866:0.009192:0.010311:0.009192:0.009223:0.003024:0.005125:0.004793:0.009903:0.004747:0.004793:0.005125:0.009223:0.009827:0.004793:0.003417:0.006985:0.005020:0.008376:0.004793:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004188:0.004778:0.003417:0.005125:0.004793:0.003024:0.005866:0.004793:0.005125:0.009223:0.009827:0.004793:0.009903:0.009223:0.003024:0.008104:0.004793:0.010311:0.003024:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.004188
approved for moderate to severe atopic dermatitis that :@0.076190:0.930978:0.485115:0.930978:0.485115:0.915195:0.076190:0.915195:0.010326:0.010311:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.003508:0.004747:0.009903:0.004551:0.003492:0.014182:0.009903:0.010357:0.009827:0.004551:0.010326:0.005125:0.009827:0.003492:0.005125:0.009903:0.003492:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.003492:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.003508:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.003508:0.005125:0.009223:0.010326:0.005125:0.004188
has failed standard therapy. Efficacy is improved when :@0.076190:0.945364:0.485130:0.945364:0.485130:0.929581:0.076190:0.929581:0.009223:0.010326:0.005866:0.004536:0.004747:0.010326:0.003024:0.003024:0.009827:0.010357:0.004551:0.005866:0.005125:0.010326:0.009223:0.010357:0.010326:0.004551:0.010357:0.004536:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.004536:0.008104:0.004747:0.003681:0.003681:0.009782:0.010326:0.009782:0.008104:0.004536:0.003024:0.005866:0.004551:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.004536:0.012564:0.009223:0.009827:0.009223:0.004188
combined with topical corticosteroids. Adverse events :@0.519042:0.084928:0.928012:0.084928:0.928012:0.069145:0.519042:0.069145:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.005549:0.012564:0.003024:0.005125:0.009223:0.005549:0.005125:0.009903:0.010311:0.003024:0.009782:0.010326:0.003024:0.005549:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.005866:0.005125:0.009827:0.004551:0.009903:0.003024:0.010357:0.005866:0.004188:0.005534:0.011188:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.005549:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004188
include injection-site  reactions,  conjunctivitis, head-:@0.519042:0.098921:0.923809:0.098921:0.923809:0.083138:0.519042:0.083138:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.011203:0.003024:0.009223:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005020:0.005866:0.003024:0.005125:0.009827:0.004188:0.007000:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004188:0.007000:0.009782:0.009903:0.009223:0.003069:0.009192:0.009223:0.009782:0.005125:0.003024:0.008376:0.003024:0.005125:0.003024:0.005866:0.004188:0.011203:0.009223:0.009827:0.010326:0.010357:0.005020
ache, nasopharyngitis, erythrodermic psoriasis and alo-:@0.519042:0.112914:0.923809:0.112914:0.923809:0.097131:0.519042:0.097131:0.010326:0.009782:0.009223:0.009827:0.004188:0.004596:0.009223:0.010326:0.005866:0.009903:0.010311:0.009223:0.010326:0.004551:0.008104:0.009223:0.010175:0.003024:0.005125:0.003024:0.005866:0.004188:0.004611:0.009827:0.004551:0.008104:0.005125:0.009223:0.004551:0.009903:0.010357:0.009827:0.004551:0.014182:0.003024:0.009782:0.004596:0.010311:0.005866:0.009903:0.004551:0.003024:0.010326:0.005866:0.003024:0.005866:0.004626:0.010326:0.009223:0.010357:0.004611:0.010326:0.003024:0.009903:0.005020
pecia areata.:@0.519042:0.126907:0.621171:0.126907:0.621171:0.111124:0.519042:0.111124:0.010311:0.009827:0.009782:0.003024:0.010326:0.004188:0.010326:0.004551:0.009827:0.010326:0.005125:0.010326:0.004188
Other potential biologics, but not approved for atop-:@0.533330:0.140900:0.923794:0.140900:0.923794:0.125117:0.533330:0.125117:0.013138:0.005125:0.009223:0.009827:0.004551:0.004400:0.010311:0.009903:0.005125:0.009827:0.009223:0.005125:0.003024:0.010311:0.003024:0.004400:0.010311:0.003024:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.005866:0.004188:0.004400:0.010311:0.009192:0.005125:0.004400:0.009223:0.009903:0.005125:0.004400:0.010326:0.010311:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.004400:0.004747:0.009903:0.004551:0.004400:0.010326:0.005125:0.009903:0.010311:0.005020
ic dermatitis, include nemolizumab, tralokinumab, leb-:@0.519042:0.154893:0.923779:0.154893:0.923779:0.139110:0.519042:0.139110:0.003024:0.009782:0.005791:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188:0.005791:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.005791:0.009223:0.009827:0.014182:0.009903:0.003024:0.003024:0.006426:0.009192:0.014182:0.010326:0.010311:0.004188:0.005791:0.005125:0.004551:0.010326:0.003024:0.009903:0.007590:0.003024:0.009223:0.009192:0.014182:0.010326:0.010311:0.004188:0.005791:0.003024:0.009827:0.010311:0.005020
rikizumab, fezakinumab, rituximab, omalizumab, janus-:@0.519042:0.168886:0.923809:0.168886:0.923809:0.153103:0.519042:0.153103:0.004551:0.003024:0.007590:0.003024:0.006426:0.009192:0.014182:0.010326:0.010311:0.004188:0.005912:0.004747:0.009827:0.006426:0.010326:0.007590:0.003024:0.009223:0.009192:0.014182:0.010326:0.010311:0.004188:0.005896:0.004551:0.003024:0.005125:0.009192:0.007257:0.003024:0.014182:0.010326:0.010311:0.004188:0.005912:0.009903:0.014182:0.010326:0.003024:0.003024:0.006426:0.009192:0.014182:0.010326:0.010311:0.004188:0.005912:0.003069:0.010326:0.009223:0.009192:0.005866:0.005020
kinase inhibitors and tezepelumab.:@0.519042:0.182879:0.773208:0.182879:0.773208:0.167096:0.519042:0.167096:0.007590:0.003024:0.009223:0.010326:0.005866:0.009827:0.004188:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.010326:0.009223:0.010357:0.004188:0.005125:0.009827:0.006426:0.009827:0.010311:0.009827:0.003024:0.009192:0.014182:0.010326:0.010311:0.004188
Antimicrobials:@0.519047:0.215380:0.634960:0.215380:0.634960:0.197048:0.519047:0.197048:0.012431:0.010079:0.005040:0.004032:0.015791:0.004032:0.010751:0.005376:0.010751:0.011087:0.004032:0.011087:0.004032:0.007392
Due to impaired skin-barrier function, patients with atop-:@0.519047:0.231548:0.923784:0.231548:0.923784:0.215765:0.519047:0.215765:0.011249:0.009192:0.009827:0.003160:0.005125:0.009903:0.003160:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.009827:0.010357:0.003160:0.005866:0.007590:0.003024:0.009223:0.005020:0.010311:0.010326:0.004551:0.004551:0.003024:0.009827:0.004551:0.003160:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.003160:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003160:0.012564:0.003024:0.005125:0.009223:0.003160:0.010326:0.005125:0.009903:0.010311:0.005020
ic dermatitis are predisposed to infections with, in par-:@0.519047:0.245541:0.923784:0.245541:0.923784:0.229758:0.519047:0.229758:0.003024:0.009782:0.005534:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.005534:0.010326:0.004551:0.009827:0.005534:0.010311:0.004551:0.009827:0.010357:0.003024:0.005866:0.010311:0.009903:0.005866:0.009827:0.010357:0.005534:0.005125:0.009903:0.005534:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.005534:0.012564:0.003024:0.005125:0.009223:0.004188:0.005534:0.003024:0.009223:0.005534:0.010311:0.010326:0.004551:0.005020
ticular, :@0.519047:0.259534:0.572448:0.259534:0.572448:0.243751:0.519047:0.243751:0.005125:0.003024:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.004188
Staphylococcus aureus:@0.571677:0.259534:0.741902:0.259534:0.741902:0.243751:0.571677:0.243751:0.007529:0.005125:0.010326:0.010311:0.009223:0.008104:0.003024:0.009903:0.009782:0.009903:0.009782:0.009782:0.009192:0.005866:0.003417:0.010326:0.009192:0.004551:0.009827:0.009192:0.005866
 and herpes simplex virus. :@0.741902:0.259534:0.927972:0.259534:0.927972:0.243751:0.741902:0.243751:0.003417:0.010326:0.009223:0.010357:0.003417:0.009223:0.009827:0.004551:0.010311:0.009827:0.005866:0.003417:0.005866:0.003024:0.014182:0.010311:0.003024:0.009827:0.007257:0.003432:0.008376:0.003024:0.004551:0.009192:0.005866:0.004188:0.004188
Ninety per cent of patients with atopic dermatitis are :@0.519047:0.273527:0.928002:0.273527:0.928002:0.257744:0.519047:0.257744:0.011188:0.003024:0.009223:0.009827:0.005125:0.008104:0.006456:0.010311:0.009827:0.004551:0.006456:0.009782:0.009827:0.009223:0.005125:0.006441:0.009903:0.004747:0.006456:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006456:0.012564:0.003024:0.005125:0.009223:0.006456:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.006456:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.006456:0.010326:0.004551:0.009827:0.004188
colonised with :@0.519047:0.287520:0.628766:0.287520:0.628766:0.271737:0.519047:0.271737:0.009782:0.009903:0.003024:0.009903:0.009223:0.003024:0.005866:0.009827:0.010357:0.004687:0.012564:0.003024:0.005125:0.009223:0.004188
S. aureus:@0.629265:0.287520:0.694625:0.287520:0.694625:0.271737:0.629265:0.271737:0.007529:0.004188:0.004687:0.010326:0.009192:0.004551:0.009827:0.009192:0.005866
. The use of systemic antibiotics :@0.694625:0.287520:0.927987:0.287520:0.927987:0.271737:0.694625:0.271737:0.004188:0.004687:0.006441:0.009223:0.009827:0.004687:0.009192:0.005866:0.009827:0.004687:0.009903:0.004747:0.004687:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.004702:0.010326:0.009223:0.005125:0.003024:0.010311:0.003024:0.009903:0.005125:0.003024:0.009782:0.005866:0.004188
is only recommended  for  overtly infected  atopic der-:@0.519047:0.301513:0.923814:0.301513:0.923814:0.285730:0.519047:0.285730:0.003024:0.005866:0.006486:0.009903:0.009223:0.003024:0.008104:0.006486:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.002283:0.004747:0.009903:0.004551:0.004188:0.002283:0.009903:0.008376:0.009827:0.004551:0.005125:0.003024:0.008104:0.006486:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.009827:0.010357:0.004188:0.002283:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.006486:0.010357:0.009827:0.004551:0.005020
matitis.  Although bleach baths have been shown to :@0.519047:0.315506:0.928004:0.315523:0.928004:0.299740:0.519047:0.299724:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188:0.009723:0.006441:0.011188:0.003024:0.005125:0.009223:0.009903:0.009192:0.010175:0.009223:0.006426:0.010311:0.003024:0.009827:0.010326:0.009782:0.009223:0.006441:0.010311:0.010326:0.005125:0.009223:0.005866:0.006441:0.009223:0.010326:0.008376:0.009827:0.006441:0.010311:0.009827:0.009827:0.009223:0.006426:0.005866:0.009223:0.009903:0.012564:0.009223:0.006426:0.005125:0.009903:-0.006809
14:@0.569912:0.310224:0.579628:0.310224:0.579628:0.301070:0.569912:0.301070:0.004858:0.004858
reduce atopic dermatitis severity, they have not been :@0.519049:0.329516:0.928004:0.329516:0.928004:0.313733:0.519049:0.313733:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.005564:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.005579:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.005579:0.005866:0.009827:0.008376:0.009827:0.004551:0.003024:0.005125:0.008104:0.004188:0.005564:0.005125:0.009223:0.009827:0.008104:0.005564:0.009223:0.010326:0.008376:0.009827:0.005579:0.009223:0.009903:0.005125:0.005564:0.010311:0.009827:0.009827:0.009223:0.004188
found to be more effective than water baths alone.:@0.519049:0.343509:0.898522:0.343509:0.898522:0.327726:0.519049:0.327726:0.004747:0.009903:0.009192:0.009223:0.010357:0.004188:0.005125:0.009903:0.004188:0.010311:0.009827:0.004188:0.014182:0.009903:0.004551:0.009827:0.004188:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.004188:0.005125:0.009223:0.010326:0.009223:0.004188:0.012564:0.010326:0.005125:0.009827:0.004551:0.004188:0.010311:0.010326:0.005125:0.009223:0.005866:0.004188:0.010326:0.003024:0.009903:0.009223:0.009827:0.004188
15:@0.898470:0.338216:0.908186:0.338216:0.908186:0.329062:0.898470:0.329062:0.004858:0.004858
Oral antihistamines:@0.519047:0.374709:0.674269:0.374709:0.674269:0.356378:0.519047:0.356378:0.014111:0.005376:0.011087:0.004032:0.004704:0.011087:0.010079:0.005040:0.004032:0.010079:0.004032:0.007392:0.005040:0.011087:0.015791:0.004032:0.010079:0.010751:0.007392
Antihistamine use in atopic dermatitis is limited. There is, :@0.519047:0.390877:0.928002:0.390877:0.928002:0.375094:0.519047:0.375094:0.011188:0.009223:0.005125:0.003024:0.009223:0.003024:0.005866:0.005125:0.010326:0.014182:0.003024:0.009223:0.009827:0.004339:0.009192:0.005866:0.009827:0.004339:0.003024:0.009223:0.004354:0.010326:0.005125:0.009903:0.010311:0.003024:0.009782:0.004354:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004354:0.003024:0.005866:0.004354:0.003024:0.003024:0.014182:0.003024:0.005125:0.009827:0.010357:0.004188:0.004354:0.006441:0.009223:0.009827:0.004551:0.009827:0.004339:0.003024:0.005866:0.004188:0.004188
however, a role for intermittent use of sedating antihis-:@0.519047:0.404870:0.923799:0.404870:0.923799:0.389087:0.519047:0.389087:0.009223:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.005216:0.010326:0.005231:0.004551:0.009903:0.003024:0.009827:0.005216:0.004747:0.009903:0.004551:0.005216:0.003024:0.009223:0.005125:0.009827:0.004551:0.014182:0.003024:0.005125:0.005125:0.009827:0.009223:0.005125:0.005216:0.009192:0.005866:0.009827:0.005231:0.009903:0.004747:0.005231:0.005866:0.009827:0.010357:0.010326:0.005125:0.003024:0.009223:0.010175:0.005231:0.010326:0.009223:0.005125:0.003024:0.009223:0.003024:0.005866:0.005020
tamines to improve sleep loss secondary to pruritus.:@0.519047:0.418863:0.893621:0.418863:0.893621:0.403081:0.519047:0.403081:0.005125:0.010326:0.014182:0.003024:0.009223:0.009827:0.005866:0.004188:0.005125:0.009903:0.004188:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.004188:0.005866:0.003024:0.009827:0.009827:0.010311:0.004188:0.003024:0.009903:0.005866:0.005866:0.004188:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.010326:0.004551:0.008104:0.004188:0.005125:0.009903:0.004188:0.010311:0.004551:0.009192:0.004551:0.003024:0.005125:0.009192:0.005866:0.004188
15:@0.893598:0.413570:0.903314:0.413570:0.903314:0.404416:0.893598:0.404416:0.004858:0.004858
referrAl:@0.519047:0.451612:0.601093:0.451612:0.601093:0.431447:0.519047:0.431447:0.010718:0.009609:0.008870:0.009609:0.010718:0.010718:0.013674:0.008131
Indications for referral to a dermatologist include::@0.519047:0.467386:0.879410:0.467386:0.879410:0.451603:0.519047:0.451603:0.003417:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004747:0.009903:0.004551:0.004188:0.004551:0.009827:0.004747:0.009827:0.004551:0.004551:0.010326:0.003024:0.004188:0.005125:0.009903:0.004188:0.010326:0.004188:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.009903:0.003024:0.009903:0.010175:0.003024:0.005866:0.005125:0.004188:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.004188
•  Uncertain diagnosis.:@0.519047:0.481379:0.682968:0.481379:0.682968:0.465596:0.519047:0.465596:0.009162:0.004188:0.003447:0.009903:0.009223:0.009782:0.009827:0.004551:0.005125:0.010326:0.003024:0.009223:0.004188:0.010357:0.003024:0.010326:0.010175:0.009223:0.009903:0.005866:0.003024:0.005866:0.004188
•  Frequent flares despite appropriate treatment.:@0.519047:0.495372:0.876295:0.495372:0.876295:0.479589:0.519047:0.479589:0.009162:0.004188:0.003447:0.007333:0.004551:0.009827:0.010311:0.009192:0.009827:0.009223:0.005125:0.004188:0.003666:0.003666:0.010326:0.004551:0.009827:0.005866:0.004188:0.010357:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.004188:0.010326:0.010311:0.010311:0.004551:0.009903:0.010311:0.004551:0.003024:0.010326:0.005125:0.009827:0.004188:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188
•  Atopic dermatitis on the face that has not responded :@0.519047:0.509365:0.927987:0.509365:0.927987:0.493582:0.519047:0.493582:0.009162:0.004188:0.003447:0.011188:0.005125:0.009903:0.010311:0.003024:0.009782:0.003689:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.003704:0.009903:0.009223:0.003689:0.005125:0.009223:0.009827:0.003689:0.004747:0.010326:0.009782:0.009827:0.003689:0.005125:0.009223:0.010326:0.005125:0.003689:0.009223:0.010326:0.005866:0.003704:0.009223:0.009903:0.005125:0.003689:0.004551:0.009827:0.005866:0.010311:0.009903:0.009223:0.010357:0.009827:0.010357:0.004188
to appropriate treatment.:@0.535845:0.523358:0.725316:0.523358:0.725316:0.507575:0.535845:0.507575:0.005125:0.009903:0.004188:0.010326:0.010311:0.010311:0.004551:0.009903:0.010311:0.004551:0.003024:0.010326:0.005125:0.009827:0.004188:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188
•  Atopic  dermatitis  causing  significant  psychosocial :@0.519047:0.537351:0.927972:0.537351:0.927972:0.521568:0.519047:0.521568:0.009162:0.004188:0.003447:0.011188:0.005125:0.009903:0.010311:0.003024:0.009782:0.004188:0.006153:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188:0.006153:0.009782:0.010326:0.009192:0.005866:0.003024:0.009223:0.010175:0.004188:0.006153:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.004188:0.006153:0.010311:0.005866:0.008104:0.009782:0.009223:0.009903:0.005866:0.009903:0.009782:0.003024:0.010326:0.003024:0.004188
problems for a child or parent.:@0.535845:0.551344:0.757701:0.551344:0.757701:0.535562:0.535845:0.535562:0.010311:0.004551:0.009903:0.010311:0.003024:0.009827:0.014182:0.005866:0.004188:0.004747:0.009903:0.004551:0.004188:0.010326:0.004188:0.009782:0.009223:0.003024:0.003024:0.010357:0.004188:0.009903:0.004551:0.004188:0.010311:0.010326:0.004551:0.009827:0.009223:0.005125:0.004188
•  Severe and recurrent infections.:@0.519047:0.565337:0.768814:0.565337:0.768814:0.549555:0.519047:0.549555:0.009162:0.004188:0.003447:0.007529:0.009827:0.008376:0.009827:0.004551:0.009827:0.004188:0.010326:0.009223:0.010357:0.004188:0.004551:0.009827:0.009782:0.009192:0.004551:0.004551:0.009827:0.009223:0.005125:0.004188:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188
•  Suspected contact dermatitis.:@0.519047:0.579330:0.756900:0.579330:0.756900:0.563548:0.519047:0.563548:0.009162:0.004188:0.003447:0.007529:0.009192:0.005866:0.010311:0.009827:0.009782:0.005125:0.009827:0.010357:0.004188:0.009782:0.009903:0.009223:0.005125:0.010326:0.009782:0.005125:0.004188:0.010357:0.009827:0.004551:0.014182:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188
•  Urgent referral:@0.519047:0.593323:0.640242:0.593323:0.640242:0.577541:0.519047:0.577541:0.009162:0.004188:0.003447:0.009903:0.004551:0.010175:0.009827:0.009223:0.005125:0.004188:0.004551:0.009827:0.004747:0.009827:0.004551:0.004551:0.010326:0.003024
 if eczema herpeticum.:@0.640211:0.593323:0.810149:0.593323:0.810149:0.577541:0.640211:0.577541:0.004188:0.003024:0.004747:0.004188:0.009827:0.009782:0.006426:0.009827:0.014182:0.010326:0.004188:0.009223:0.009827:0.004551:0.010311:0.009827:0.005125:0.003024:0.009782:0.009192:0.014182:0.004188
referenCes:@0.519047:0.626092:0.625485:0.626092:0.625485:0.605927:0.519047:0.605927:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1.  Williams H,  Flohr  C.  How  epidemiology has challenged  3 prevail-:@0.519047:0.640436:0.923789:0.640436:0.923789:0.628161:0.519047:0.628161:0.006515:0.003257:0.003257:0.007126:0.011289:0.002352:0.002352:0.002352:0.002352:0.008032:0.011030:0.004563:0.005621:0.008032:0.003257:0.003257:0.002352:0.005703:0.002352:0.007702:0.007173:0.003540:0.003257:0.002352:0.009560:0.003257:0.003257:0.002352:0.008032:0.007702:0.009772:0.003257:0.002352:0.007644:0.008020:0.002352:0.008055:0.007644:0.011030:0.002352:0.007702:0.002352:0.007702:0.007914:0.006303:0.005621:0.007173:0.008032:0.004563:0.005621:0.007608:0.007173:0.008032:0.002352:0.002352:0.007644:0.007173:0.007914:0.007644:0.008055:0.003257:0.002352:0.006515:0.005621:0.008020:0.003540:0.007644:0.006515:0.008032:0.002352:0.002352:0.003904
ing concepts about atopic dermatitis. :@0.539203:0.651221:0.777198:0.651221:0.777198:0.638946:0.539203:0.638946:0.002352:0.007173:0.007914:0.007902:0.007608:0.007702:0.007173:0.007608:0.007644:0.008020:0.003986:0.004563:0.007902:0.008032:0.008020:0.007702:0.007150:0.003986:0.007902:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.007902:0.008055:0.007644:0.003540:0.011030:0.008032:0.003986:0.002352:0.003986:0.002352:0.004563:0.003257:0.003257
J Allergy Clin Immunol.:@0.781843:0.651221:0.923812:0.651221:0.923812:0.638946:0.781843:0.638946:0.005668:0.007902:0.008702:0.002352:0.002352:0.007644:0.003540:0.007914:0.006303:0.007902:0.009560:0.002352:0.002352:0.007173:0.007902:0.002658:0.011030:0.011030:0.007150:0.007173:0.007702:0.002352:0.003257
 :@0.923812:0.651221:0.927070:0.651221:0.927070:0.638946:0.923812:0.638946:0.003257
2006;118(1):209-13.:@0.539203:0.662006:0.646247:0.662006:0.646247:0.649730:0.539203:0.649730:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
2.  Williams H,  Robertson  C,  stewart  A, :@0.519047:0.672791:0.750199:0.672791:0.750199:0.660515:0.519047:0.660515:0.006515:0.003257:0.003257:0.007126:0.011289:0.002352:0.002352:0.002352:0.002352:0.008032:0.011030:0.004563:0.005421:0.008032:0.003257:0.003257:0.002152:0.007138:0.007702:0.008020:0.007644:0.003540:0.003986:0.004563:0.007702:0.007173:0.003257:0.002152:0.009560:0.003257:0.003257:0.002164:0.005856:0.003986:0.007644:0.009772:0.008032:0.003540:0.003986:0.003257:0.002152:0.008702:0.003257:0.003257
et  al:@0.752351:0.672791:0.779773:0.672791:0.779773:0.660515:0.752351:0.660515:0.007644:0.003986:0.003257:0.002152:0.008032:0.002352
.  Worldwide  variations in :@0.779773:0.672791:0.927058:0.672791:0.927058:0.660515:0.779773:0.660515:0.003257:0.003257:0.002152:0.011289:0.007702:0.003540:0.002352:0.008055:0.009772:0.002352:0.008055:0.007644:0.003257:0.002152:0.006515:0.008032:0.003540:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.005421:0.002352:0.007173:0.003257
the prevalence of symptoms of atopic eczema in the International :@0.539203:0.683575:0.927058:0.683575:0.927058:0.671300:0.539203:0.671300:0.003986:0.007173:0.007644:0.003869:0.008020:0.003540:0.007644:0.006515:0.008032:0.002352:0.007644:0.007173:0.007608:0.007644:0.003869:0.007702:0.003692:0.003869:0.004563:0.006303:0.011030:0.008020:0.003986:0.007702:0.011030:0.004563:0.003881:0.007702:0.003692:0.003869:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.003881:0.007644:0.007608:0.004998:0.007644:0.011030:0.008032:0.003869:0.002352:0.007173:0.003881:0.003986:0.007173:0.007644:0.003869:0.002658:0.007173:0.003986:0.007644:0.003540:0.007173:0.008032:0.003986:0.002352:0.007702:0.007173:0.008032:0.002352:0.003257
study of Asthma and Allergies in Childhood. :@0.539203:0.694360:0.794049:0.694360:0.794049:0.682085:0.539203:0.682085:0.005856:0.003986:0.007150:0.008055:0.006303:0.003692:0.007702:0.003692:0.003681:0.008702:0.004563:0.003986:0.007173:0.011030:0.008032:0.003681:0.008032:0.007173:0.008055:0.003692:0.008702:0.002352:0.002352:0.007644:0.003540:0.007914:0.002352:0.007644:0.004563:0.003692:0.002352:0.007173:0.003692:0.009560:0.007173:0.002352:0.002352:0.008055:0.007173:0.007702:0.007702:0.008055:0.003257:0.003257
J Allergy Clin Immunol:@0.794472:0.694360:0.920543:0.694360:0.920543:0.682085:0.794472:0.682085:0.005668:0.003692:0.008702:0.002352:0.002352:0.007644:0.003540:0.007914:0.006303:0.003681:0.009560:0.002352:0.002352:0.007173:0.003692:0.002658:0.011030:0.011030:0.007150:0.007173:0.007702:0.002352
. :@0.920543:0.694360:0.927058:0.694360:0.927058:0.682085:0.920543:0.682085:0.003257:0.003257
1999;103(1 pt 1):125-38.:@0.539203:0.705145:0.670224:0.705145:0.670224:0.692869:0.539203:0.692869:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.003257:0.006961:0.003986:0.003257:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
3.  Chalmers DA, Todd G, saxe N, :@0.519047:0.715930:0.718414:0.715930:0.718414:0.703654:0.519047:0.703654:0.006515:0.003257:0.003257:0.007126:0.009560:0.007173:0.008032:0.002352:0.011030:0.007644:0.003540:0.004563:0.003975:0.008749:0.008702:0.003257:0.003975:0.005009:0.007702:0.008055:0.008055:0.003975:0.010254:0.003257:0.003986:0.005856:0.008032:0.005644:0.007644:0.003975:0.008702:0.003257:0.003257
et al:@0.719143:0.715930:0.745131:0.715930:0.745131:0.703654:0.719143:0.703654:0.007644:0.003986:0.003975:0.008032:0.002352
. Validation of the U.K. Working :@0.745131:0.715930:0.927058:0.715930:0.927058:0.703654:0.745131:0.703654:0.003257:0.003975:0.008255:0.008032:0.002352:0.002352:0.008055:0.008032:0.003986:0.002352:0.007702:0.007173:0.003986:0.007702:0.003692:0.003975:0.003986:0.007173:0.007644:0.003975:0.007702:0.003257:0.006950:0.003257:0.003975:0.011289:0.007702:0.003540:0.005903:0.002352:0.007173:0.007914:0.003257
party diagnostic criteria for atopic eczema in a Xhosa-speaking Afri-:@0.539203:0.726714:0.923801:0.726714:0.923801:0.714439:0.539203:0.714439:0.006961:0.008032:0.003540:0.003986:0.006303:0.003057:0.008055:0.002352:0.008032:0.007914:0.007173:0.007702:0.004563:0.003986:0.002352:0.007608:0.003057:0.007608:0.003540:0.002352:0.003986:0.007644:0.003540:0.002352:0.008032:0.003057:0.003692:0.007702:0.003540:0.003057:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.003057:0.007644:0.007608:0.004998:0.007644:0.011030:0.008032:0.003057:0.002352:0.007173:0.003057:0.008032:0.003057:0.007161:0.007173:0.007702:0.004563:0.008032:0.003904:0.004563:0.008020:0.007644:0.008032:0.005903:0.002352:0.007173:0.007914:0.003057:0.008702:0.003692:0.003540:0.002352:0.003904
can population. :@0.539203:0.737499:0.634276:0.737499:0.634276:0.725224:0.539203:0.725224:0.007608:0.008032:0.007173:0.003257:0.008020:0.007702:0.008020:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
Br J Dermatol:@0.634264:0.737499:0.709771:0.737499:0.709771:0.725224:0.634264:0.725224:0.006750:0.003540:0.003257:0.005668:0.003257:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352
. 2007;156(1):111-6.:@0.709759:0.737499:0.816803:0.737499:0.816803:0.725224:0.709759:0.725224:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257
4.  Eichenfield LF, Tom WL, Berger TG, :@0.519036:0.748284:0.739851:0.748284:0.739851:0.736008:0.519036:0.736008:0.006515:0.003257:0.003257:0.007126:0.006303:0.002352:0.007608:0.007173:0.007644:0.007173:0.002863:0.002863:0.007644:0.002352:0.008055:0.004351:0.005433:0.005703:0.003257:0.004339:0.005009:0.007702:0.011030:0.004339:0.011289:0.005433:0.003257:0.004339:0.006750:0.007644:0.003540:0.007914:0.007644:0.003540:0.004339:0.005009:0.010254:0.003257:0.003257
et al:@0.740956:0.748284:0.767309:0.748284:0.767309:0.736008:0.740956:0.736008:0.007644:0.003986:0.004339:0.008032:0.002352
. Guidelines of care for the :@0.767309:0.748284:0.927046:0.748284:0.927046:0.736008:0.767309:0.736008:0.003257:0.004351:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.004351:0.007702:0.003692:0.004351:0.007608:0.008032:0.003540:0.007644:0.004339:0.003692:0.007702:0.003540:0.004339:0.003986:0.007173:0.007644:0.003257
management  of  atopic dermatitis:  section  2. Management  and :@0.539191:0.759068:0.927046:0.759068:0.927046:0.746793:0.539191:0.746793:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.002775:0.007702:0.003692:0.003257:0.002775:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.006044:0.008055:0.007644:0.003540:0.011030:0.008032:0.003986:0.002352:0.003986:0.002352:0.004563:0.003257:0.003257:0.002787:0.005856:0.007644:0.007608:0.003986:0.002352:0.007702:0.007173:0.003257:0.002775:0.006515:0.003257:0.006044:0.010807:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.002775:0.008032:0.007173:0.008055:0.003257
treatment  of atopic dermatitis with topical therapies. :@0.539191:0.769853:0.854045:0.769853:0.854045:0.757578:0.539191:0.757578:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.003257:0.001799:0.007702:0.003692:0.005068:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.005068:0.008055:0.007644:0.003540:0.011030:0.008032:0.003986:0.002352:0.003986:0.002352:0.004563:0.005068:0.009772:0.002352:0.003986:0.007173:0.005068:0.003986:0.007702:0.008020:0.002352:0.007608:0.008032:0.002352:0.005068:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.002352:0.007644:0.004563:0.003257:0.003257
J Am Acad :@0.855856:0.769853:0.927046:0.769853:0.927046:0.757578:0.855856:0.757578:0.005668:0.005068:0.008702:0.011030:0.005068:0.008702:0.007608:0.008032:0.008055:0.003257
Dermatol.:@0.539191:0.780773:0.595482:0.780773:0.595482:0.768497:0.539191:0.768497:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257
 2014;71(1):116-32.:@0.595482:0.780773:0.699270:0.780773:0.699270:0.768497:0.595482:0.768497:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
5.  Van Zuuren EJ, Fedorowicz Z, Christensen R, :@0.519036:0.791692:0.782443:0.791692:0.782443:0.779417:0.519036:0.779417:0.006515:0.003257:0.003257:0.007126:0.008255:0.008032:0.007173:0.002211:0.005644:0.007150:0.007150:0.003540:0.007644:0.007173:0.002211:0.006303:0.005668:0.003257:0.002211:0.005703:0.007644:0.008055:0.007702:0.003540:0.007702:0.009772:0.002352:0.007608:0.004998:0.002211:0.005644:0.003257:0.002211:0.009560:0.007173:0.003540:0.002352:0.004563:0.003986:0.007644:0.007173:0.004563:0.007644:0.007173:0.002211:0.007138:0.003257:0.003257
et al:@0.781396:0.791692:0.805620:0.791692:0.805620:0.779417:0.781396:0.779417:0.007644:0.003986:0.002211:0.008032:0.002352
. Emollients and mois-:@0.805620:0.791692:0.923789:0.791692:0.923789:0.779417:0.805620:0.779417:0.003257:0.002211:0.006303:0.011030:0.007702:0.002352:0.002352:0.002352:0.007644:0.007173:0.003986:0.004563:0.002222:0.008032:0.007173:0.008055:0.002211:0.011030:0.007702:0.002352:0.004563:0.003904
turisers for eczema. :@0.539191:0.802611:0.651080:0.802611:0.651080:0.790336:0.539191:0.790336:0.003986:0.007150:0.003540:0.002352:0.004563:0.007644:0.003540:0.004563:0.003081:0.003692:0.007702:0.003528:0.003093:0.007644:0.007608:0.004998:0.007644:0.011030:0.008032:0.003246:0.003257
Cochrane Database Syst Rev:@0.650916:0.802611:0.817673:0.802611:0.817673:0.790336:0.650916:0.790336:0.009560:0.007702:0.007608:0.007173:0.003540:0.008032:0.007173:0.007644:0.003081:0.008749:0.008032:0.003986:0.008032:0.008020:0.008032:0.004563:0.007644:0.003093:0.005856:0.006303:0.004563:0.003986:0.003093:0.007138:0.007644:0.006515
. 2017;2:CD012119.:@0.817673:0.802611:0.923765:0.802611:0.923765:0.790336:0.817673:0.790336:0.003257:0.003093:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.003257:0.009560:0.008749:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257
6.  schmitt J, von Kobyletzki L, svensson A, :@0.519036:0.813531:0.760159:0.813531:0.760159:0.801256:0.519036:0.801256:0.006515:0.003257:0.003257:0.007126:0.005856:0.007608:0.007173:0.011030:0.002352:0.003986:0.003986:0.002893:0.005668:0.003257:0.002893:0.006515:0.007702:0.007173:0.002893:0.006950:0.007702:0.008020:0.006303:0.002352:0.007644:0.003986:0.004998:0.005903:0.002352:0.002893:0.005433:0.003257:0.002893:0.005856:0.006515:0.007644:0.007173:0.004563:0.004563:0.007702:0.007173:0.002893:0.008702:0.003257:0.003257
et al:@0.759794:0.813531:0.784701:0.813531:0.784701:0.801256:0.759794:0.801256:0.007644:0.003986:0.002893:0.008032:0.002352
. Efficacy and tolerability :@0.784701:0.813531:0.927046:0.813531:0.927046:0.801256:0.784701:0.801256:0.003257:0.002893:0.006303:0.003692:0.002863:0.002863:0.007608:0.008032:0.007608:0.006303:0.002893:0.008032:0.007173:0.008055:0.002893:0.003986:0.007702:0.002352:0.007644:0.003540:0.008032:0.008020:0.002352:0.002352:0.002352:0.003986:0.006303:0.003257
of proactive treatment with topical corticosteroids and calcineurin :@0.539191:0.824450:0.927035:0.824450:0.927035:0.812175:0.539191:0.812175:0.007702:0.003692:0.004045:0.008020:0.003540:0.007702:0.008032:0.007608:0.003986:0.002352:0.006515:0.007644:0.004045:0.003986:0.003540:0.007644:0.008032:0.003986:0.011018:0.007644:0.007173:0.003986:0.004045:0.009772:0.002352:0.003986:0.007173:0.004045:0.003986:0.007702:0.008020:0.002352:0.007608:0.008032:0.002352:0.004045:0.007608:0.007702:0.003540:0.003986:0.002352:0.007608:0.007702:0.004563:0.003986:0.007644:0.003540:0.007702:0.002352:0.008055:0.004563:0.004033:0.008032:0.007173:0.008055:0.004045:0.007608:0.008032:0.002352:0.007608:0.002352:0.007173:0.007644:0.007150:0.003540:0.002352:0.007173:0.003257
inhibitors for atopic eczema: systematic review and meta-analysis of :@0.539191:0.835370:0.927035:0.835370:0.927035:0.823094:0.539191:0.823094:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.004563:0.002634:0.003692:0.007702:0.003540:0.002634:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.002634:0.007644:0.007608:0.004998:0.007644:0.011030:0.008032:0.003257:0.002634:0.005856:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.002634:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.002634:0.008032:0.007173:0.008055:0.002634:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.002646:0.007702:0.003692:0.003257
randomized controlled trials. :@0.539191:0.846289:0.703738:0.846289:0.703738:0.834014:0.539191:0.834014:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004998:0.007644:0.008055:0.003257:0.007608:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.002352:0.007644:0.008055:0.003257:0.003986:0.003540:0.002352:0.008032:0.002352:0.004563:0.003257:0.003257
Br J Dermatol:@0.703726:0.846289:0.779232:0.846289:0.779232:0.834014:0.703726:0.834014:0.006750:0.003540:0.003257:0.005668:0.003257:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352
. 2011;164(2):415-28.:@0.779221:0.846289:0.892780:0.846289:0.892780:0.834014:0.779221:0.834014:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
7.  Gonzalez-Lopez  G, Ceballos-Rodriguez  RM,  Gonzalez-Lopez  JJ, :@0.519036:0.857209:0.910195:0.857209:0.910195:0.844933:0.519036:0.844933:0.006515:0.003257:0.003257:0.007126:0.010254:0.007702:0.007173:0.004998:0.008032:0.002352:0.007644:0.004998:0.003904:0.005433:0.007702:0.008020:0.007644:0.004998:0.003257:0.001964:0.010254:0.003257:0.005233:0.009560:0.007644:0.008020:0.008032:0.002352:0.002352:0.007702:0.004563:0.003904:0.007138:0.007702:0.008055:0.003540:0.002352:0.007914:0.007150:0.007644:0.004998:0.003257:0.001964:0.007138:0.010807:0.003257:0.003257:0.001964:0.010254:0.007702:0.007173:0.004998:0.008032:0.002352:0.007644:0.004998:0.003904:0.005433:0.007702:0.008020:0.007644:0.004998:0.003257:0.001964:0.005668:0.005668:0.003257:0.003257
et :@0.912171:0.857209:0.927058:0.857209:0.927058:0.844933:0.912171:0.844933:0.007644:0.003986:0.003257
al:@0.539191:0.868128:0.549574:0.868128:0.549574:0.855853:0.539191:0.855853:0.008032:0.002352
. Efficacy and safety of wet wrap therapy for patients with atopic :@0.549574:0.868128:0.927058:0.868128:0.927058:0.855853:0.549574:0.855853:0.003257:0.003610:0.006303:0.003692:0.002863:0.002863:0.007608:0.008032:0.007608:0.006303:0.003610:0.008032:0.007173:0.008055:0.003610:0.004563:0.008032:0.003692:0.007644:0.003986:0.006303:0.003610:0.007702:0.003692:0.003598:0.009772:0.007644:0.003986:0.003610:0.009772:0.003540:0.008032:0.008020:0.003610:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.003610:0.003692:0.007702:0.003540:0.003598:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003610:0.009772:0.002352:0.003986:0.007173:0.003610:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.003257
dermatitis:  A  systematic review  and  meta-analysis. :@0.539191:0.879047:0.838723:0.879047:0.838723:0.866772:0.539191:0.866772:0.008055:0.007644:0.003540:0.011030:0.008032:0.003986:0.002352:0.003986:0.002352:0.004563:0.003257:0.003257:0.002093:0.008702:0.003257:0.002093:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.005362:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003257:0.002093:0.008032:0.007173:0.008055:0.003257:0.002093:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003257:0.003257
Br  J  Dermatol.:@0.840827:0.879047:0.923777:0.879047:0.923777:0.866772:0.840827:0.866772:0.006750:0.003540:0.003257:0.002093:0.005668:0.003257:0.002093:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257
 :@0.923777:0.879047:0.927035:0.879047:0.927035:0.866772:0.923777:0.866772:0.003257
2017;177(3):688-95.:@0.539191:0.889967:0.646235:0.889967:0.646235:0.877692:0.539191:0.877692:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
8.  Cury Martins J, Martins C, Aoki V, :@0.519036:0.900886:0.728774:0.900886:0.728774:0.888611:0.519036:0.888611:0.006515:0.003257:0.003257:0.007126:0.009560:0.007150:0.003540:0.006303:0.003492:0.010807:0.008032:0.003540:0.003986:0.002352:0.007173:0.004563:0.003492:0.005668:0.003257:0.003492:0.010807:0.008032:0.003540:0.003986:0.002352:0.007173:0.004563:0.003492:0.009560:0.003257:0.003492:0.008702:0.007702:0.005903:0.002352:0.003492:0.008255:0.003257:0.003257
et al:@0.729009:0.900886:0.754515:0.900886:0.754515:0.888611:0.729009:0.888611:0.007644:0.003986:0.003492:0.008032:0.002352
. Topical tacrolimus for atopic :@0.754515:0.900886:0.927023:0.900886:0.927023:0.888611:0.754515:0.888611:0.003257:0.003492:0.005009:0.007702:0.008020:0.002352:0.007608:0.008032:0.002352:0.003492:0.003986:0.008032:0.007608:0.003540:0.007702:0.002352:0.002352:0.011030:0.007150:0.004563:0.003492:0.003692:0.007702:0.003540:0.003492:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.003257
dermatitis. :@0.539191:0.911806:0.601244:0.911806:0.601244:0.899530:0.539191:0.899530:0.008055:0.007644:0.003540:0.011030:0.008032:0.003986:0.002352:0.003986:0.002352:0.004563:0.003257:0.003257
Cochrane Database Syst Rev:@0.601244:0.911806:0.768508:0.911806:0.768508:0.899530:0.601244:0.899530:0.009560:0.007702:0.007608:0.007173:0.003540:0.008032:0.007173:0.007644:0.003257:0.008749:0.008032:0.003986:0.008032:0.008020:0.008032:0.004563:0.007644:0.003257:0.005856:0.006303:0.004563:0.003986:0.003257:0.007138:0.007644:0.006515
. 2015(7):CD009864.:@0.768508:0.911806:0.880186:0.911806:0.880186:0.899530:0.768508:0.899530:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.009560:0.008749:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257
9.  El-Batawy MM, Bosseila MA, Mashaly HM, :@0.519036:0.922725:0.780444:0.922725:0.780444:0.910450:0.519036:0.910450:0.006515:0.003257:0.003257:0.007126:0.006303:0.002352:0.003904:0.006750:0.008032:0.003986:0.008032:0.009772:0.006303:0.004327:0.010807:0.010807:0.003257:0.004316:0.006750:0.007702:0.004563:0.004563:0.007644:0.002352:0.002352:0.008032:0.004327:0.010807:0.008702:0.003257:0.004316:0.010807:0.008032:0.004563:0.007173:0.008032:0.002352:0.006303:0.004327:0.008032:0.010807:0.003257:0.003257
et al:@0.781502:0.922725:0.807831:0.922725:0.807831:0.910450:0.781502:0.910450:0.007644:0.003986:0.004316:0.008032:0.002352
. Topical calcineurin :@0.807831:0.922725:0.927035:0.922725:0.927035:0.910450:0.807831:0.910450:0.003257:0.004316:0.005009:0.007702:0.008020:0.002352:0.007608:0.008032:0.002352:0.004316:0.007608:0.008032:0.002352:0.007608:0.002352:0.007173:0.007644:0.007150:0.003540:0.002352:0.007173:0.003257
inhibitors in atopic dermatitis: a systematic review and meta-analy-:@0.539191:0.933645:0.923742:0.933645:0.923742:0.921369:0.539191:0.921369:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.004563:0.003763:0.002352:0.007173:0.003763:0.008032:0.003986:0.007702:0.008020:0.002352:0.007608:0.003763:0.008055:0.007644:0.003540:0.011030:0.008032:0.003986:0.002352:0.003986:0.002352:0.004563:0.003257:0.003763:0.008032:0.003763:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.003763:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003763:0.008032:0.007173:0.008055:0.003763:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.003904
sis. :@0.539191:0.944564:0.557183:0.944564:0.557183:0.932289:0.539191:0.932289:0.004563:0.002352:0.004563:0.003257:0.003257
J Dermatol Sci.:@0.557183:0.944564:0.641473:0.944564:0.641473:0.932289:0.557183:0.932289:0.005668:0.003257:0.008749:0.007644:0.003540:0.011030:0.008032:0.003986:0.007702:0.002352:0.003257:0.005856:0.007608:0.002352:0.003257
 2009;54(2):76-87.:@0.641473:0.944564:0.738745:0.944564:0.738745:0.932289:0.641473:0.932289:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257